Atomo Diagnostics Limited (Atomo) and BBI Solutions (BBI) are pleased to announce that they have entered into a strategic business arrangement under which both parties have agreed to share business development efforts to bring together their unique and complimentary technology, knowhow and IP in order to meet their customers’ rapid diagnostics needs.
By combining the offering of Atomo’s unique fully integrated rapid test platforms with BBI’s deep expertise in lateral flow assay development, manufacturing, and digital app solutions, the parties are able to build on their successful existing partnership. The non-exclusive agreement will allow both parties to offer full design, development and production solutions to those looking to bring new tests to market, and expand existing portfolios, as the rapid diagnostics market continues to grow and evolve post-pandemic.
Atomo CEO John Kelly said “Atomo and BBI have had the opportunity to work together in the past and this extended agreement seeks to strengthen the relationship such that both parties can reach a broader audience, particularly in the UK and Europe and Asia-Pacific where BBI has extensive business infrastructure, with a full-service rapid diagnostics solution. This is a tremendous opportunity for us to accelerate growth across international markets and a recognition by both parties of their unique skill sets being applicable to the growing consumer focused rapid test market where ease of use and app functionality are critical.”
BBI Solutions CEO Mario Gualano wrote “I am delighted that our relationship with Atomo continues to strengthen extending our flexible solutions to drive and deliver exceptional products for our customers evolving needs. The opportunity to combine BBI’s expertise and commercial reach in lateral flow development and manufacture, and BBI’s patented NovarumTM digital technology, with the flexibility and quality of Atomo’s integrated platforms, creates value and offers an elegant solution for our customers”.